Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

ARGX

Phase 1b

ARGX -119

Congenital myasthenic syndrome (CMS)

H2 2025

Ph1 trial ongoing. Ph1b/2a to start by end of 2024. 3/7/25- Trial presentation at AAN '25 on April 8, 2025. 2/27/25- Ph1b topline data in H2 2025.

Data readout

RVMD

Phase 3

Daraxonrasib (RMC-6236)

1L metastatic pancreatic ductal adenocarcinoma

H2 2025

2/26/25- To initiate Ph3 trial in H2 2025.

Initiation

IMTX

Phase 1

TCER® IMA401 (MAGEA4/8)

Solid tumors

2025

Collab w/ BMY. 8/17/23- Ph 1 trial ongoing. 03/21/24- Clinical data update in H2 2024. 9/16/24- Presented the proof-of-concept clinical data at ESMO '24. Next data update expected in 2025.

Data readout

IMAB

Phase 1b

Givastomig (TJ-CD4B/ABL111)

Advanced Solid tumors, metastatic gastric cancer

Early H2 2025

9/16/24- Ph1 updated expansion data at ESMO 2024. New combo cohort w/ nivolumab & chemotherapy & in collab. w/ BMY is ongoing. 1/6/25- Prioritized as lead clinical program. Present data in the early H2 2025 w/ expansion to additional cohort and data in early 2026.

Data readout

AMRX

PDUFA

Denosumab Biosimilars

Osteoporosis

Q4 2025

Denosumab biosimilar candidates reference Prolia® and XGEVA®. 3/4/25- BLA accepted. PDUFA target action date Q4 2025

Approval decision

EXEL

Phase 3

Zanzalintinib

Advanced Non-Clear Cell Kidney Cancer (nccRCC)

H2 2025

STELLAR-304 trial. Currently ongoing. 2/11/25- Topline data in H2 2025.

Data Readout

KRYS

Phase 1

KB408

Type 1 Alpha-1 Antitrypsin Deficiency

H2 2025

SERPENTINE-1 trial. 02/24- Dosed first patient. 5/6/24- Interim data in Q4 2024. 12/12/24- safe & well-tolerated at all dosing regimen. 2/19/25- Expanded Cohort 2 and opened Cohort 3, result in H2 2025.

Additional data readout

KRYS

Phase 1

KB304

Wrinkles

H2 2025

PEARL-2 study. Collab w/ Jeune Aesthetics. 11/2024- Initiated dosing in Ph1 PEARL-2 study. 2/19/25- Topline data in H2 2025.

Data readout

XNCR

Phase 1

XmAb819 (ENPP3 x CD3)

Advanced clear-cell renal cell carcinoma (ccRCC)

H2 2025

9/9/24 Shows encouraging clinical activity in Ph1. Reach target dose levels by YE & update on initiation of the first dose expansion cohort in H1 2025. 2/27/25- Initial data in H2 2025.

Data readout

ARGX

Phase 1

ARGX-109

IL-6 Inhibitor; Inflammation

H2 2025

2/27/25- Ph1 trial ongoing, topline results expected in H2 2025

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20